Patents by Inventor Francis Thomas Boyle
Francis Thomas Boyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110003831Abstract: The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.Type: ApplicationFiled: September 13, 2010Publication date: January 6, 2011Applicant: ASTRAZENECA ABInventors: David Williams Tonge, Sian Tomiko Taylor, Francis Thomas Boyle, Andrew Mark Hughes, Donna Johnson, Marianne Bernice Ashford, Nigel Charles Barrass
-
Patent number: 7820679Abstract: The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.Type: GrantFiled: August 20, 2003Date of Patent: October 26, 2010Assignee: AstraZeneca ABInventors: David William Tonge, Sian Tomiko Taylor, Francis Thomas Boyle, Andrew Mark Hughes, Donna Johnstone, Marianne Bernice Ashford, Nigel Charles Barrass
-
Publication number: 20100035896Abstract: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent.Type: ApplicationFiled: June 12, 2009Publication date: February 11, 2010Applicant: ASTRAZENECA ABInventors: John Curwen, Andrew Hughes, Donna Johnstone, Francis Thomas Boyle, Gwen Boyle
-
Patent number: 7504416Abstract: The invention concerns compounds of formula (I), wherein each of R1, R2, R3, R4, R5, R6, R8, R9, R10 m, n, p, X, Y and Z have any meanings defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-proliferative agent in the treatment of solid tumor disease.Type: GrantFiled: July 16, 2007Date of Patent: March 17, 2009Assignee: AstraZeneca ABInventors: Francis Thomas Boyle, Keith Hopkinson Gibson
-
Patent number: 7449489Abstract: The invention relates to a group of novel indole compounds of Formula (I): wherein: R1, R2, R4, R6, R6a, R7, R8, R9, R10, and A are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.Type: GrantFiled: August 18, 2003Date of Patent: November 11, 2008Assignee: AstraZeneca ABInventors: Francis Thomas Boyle, Robert Davies, Zbigniew Matusiak, Michael Wardleworth
-
Patent number: 7402583Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof, a process for t he preparation of a compound of Formula (1a) and pharmaceutical compositions of a compound of Formula (1a).Type: GrantFiled: March 14, 2006Date of Patent: July 22, 2008Assignee: AstrZenca ABInventors: Francis Thomas Boyle, Keith Hopkinson Gibson, Kevin Michael Foote
-
Patent number: 7253184Abstract: The invention concerns compounds of formula (I), wherein each of R1, R2, R3, R4, R5, R6, R8, R9, R10 m, n, p, X, Y and Z have any meanings defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-proliferative agent in the treatment of solid tumour disease.Type: GrantFiled: October 25, 2001Date of Patent: August 7, 2007Assignee: AstraZeneca ABInventors: Francis Thomas Boyle, Keith Hopkinson Gibson
-
Patent number: 7101897Abstract: This invention relates to compounds of formula (I) that inhibit farnesylation of gene products through inhibition of the enzyme farnesyl-protein transferase (FPTase). The invention also relates to methods of manufacturing the compounds, pharmaceutical compositions and methods of treating diseases, especially cancer, which are mediated through farnesylation.Type: GrantFiled: December 18, 2000Date of Patent: September 5, 2006Assignee: AstraZeneca ABInventors: James Michael Wardleworth, Francis Thomas Boyle, Zbigniew Matusiak
-
Patent number: 7067532Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt pro-drug or solvate thereof. The invention also provides a process for the preparation of a compound of Formula (Ia), pharmaceutical compositions of a compound of Formula (Ia) and methods for the treatment or prevention of cancer comprising administering an effective amount of a compound of Formula (Ia).Type: GrantFiled: October 26, 2001Date of Patent: June 27, 2006Assignee: AstraZenecaInventors: Francis Thomas Boyle, Keith Hopkinson Gibson, Kevin Michael Foote
-
Patent number: 7030123Abstract: The invention provides a compound of Formula (I). Wherein R1, R2, R3, R10 and R11 have the meanings given in the description. Such compounds are predicted to cause the selective destruction of tumour vasculature. They may therefore be used to inhibit and/or reverse, and/or alleviate symptoms of angiogenesis and/or any disease state associated with angiogenesis.Type: GrantFiled: May 25, 2001Date of Patent: April 18, 2006Assignee: AstraZeneca ABInventors: Jean-Claude Arnould, Thomas Geoffrey Bird, Francis Thomas Boyle, David Charles Blakey
-
Patent number: 6946468Abstract: The present invention relates to inhibitors of ras farnesylation of the Formula I wherein: R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CH2—NH— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing upto 5 heteroatoms where the heteroatoms are independently selected from O, N & S; or a —S—S— dimer thereof when R2?H; or a N-oxide or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation their use as therapeutic agents and pharmaceutical compositions containing them.Type: GrantFiled: August 13, 1997Date of Patent: September 20, 2005Assignee: Zeneca LimitedInventors: Francis Thomas Boyle, James Michael Wardleworth
-
Patent number: 6777438Abstract: This invention relates to compounds of formula (I) that inhibit farnesylation of gene products through inhibition of the enzyme farnesyl-protein transferase (FPTase). The invention also relates to methods of manufacturing the compounds, pharmaceutical compositions and methods of treating diseases, especially cancer, which are mediated through farnesylation.Type: GrantFiled: June 20, 2002Date of Patent: August 17, 2004Assignee: AstraZeneca ABInventors: James Michael Wardleworth, Francis Thomas Boyle, Zbigniew Matusiak
-
Publication number: 20040110775Abstract: The present invention relates to a series of CDK-inhibiting purine derivatives of structural formula (I), or a pharmaceutically acceptable salt and/or prodrug form thereof, wherein: X is O, S or CHRX where RX is H or C1-14 alkyl; D is NZ1Z2 where Z1 is selected from H, C1-4 alkyl, C1-4 hydroxyalkyl, an unsubstituted or substituted aryl or heteroaryl, and an unsubstituted or substituted aralkyl or heteroaralkyl group, and Z2 is selected from an unsubstituted or substituted aryl or heteroaryl, and an unsubstituted or substituted aralkyl or heteroaralkyl group; A is selected from H, C1-4 alkyl, C1-4 alkoxy, hydroxy, CH2(CH2)nOH (n=1-4), and NRa1Ra2 where Ra1 and Ra2 are each independently H or C1-4 alkyl; B is selected from H, halo, C1-4 alkyl, C1-4 alkoxy, CF3, an optionally substituted aryl or an optionally substituted aralkyl, and a hydroxy group that may undergo a C═O tautomeric rearrangement; and Y comprises an unsubstituted or substituted 4- to 8-membered carbocyclic or heterocyclic ring, optioType: ApplicationFiled: January 6, 2004Publication date: June 10, 2004Inventors: Roger John Griffin, Alan Hilary Calvert, Nicola Jane Curtin, Bernard Thomas Golding, Ian Robert Hardcastle, David Richard Newell, Philip John Jewsbury, Francis Thomas Boyle, Jane Anne Endicott, Martin Edward Mantyla Noble
-
Publication number: 20040029898Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt. prodrug or solvate thereof. The invention also provides a process for the preparation of a compound of Formula (Ia), pharmaceutical compositions of a compound of Formula (Ia) and methods for the treatment or prevention of cancer comprising administering an effective amount of a compound of Formula (Ia).Type: ApplicationFiled: May 2, 2003Publication date: February 12, 2004Inventors: Francis Thomas Boyle, Keith Hopkinson Gibson, Kevin Michael Foote
-
Publication number: 20030220495Abstract: The present invention relates to inhibitors of ras farnesylation of Formula (1), wherein T is of Formula (1) or (2) or (3), A is aryl or heteroaryl; B is aryl or heteroaryl; X and Y represent hydrogen, or both X and Y can represent a single bond (so as to form a double bond); R1 represents a group of Formula (II) or (III), the group of Formula (II) or Formula (III) (having L or D configuration at the chiral alpha carbon in the corresponding free amino acid); R2 represents hydrogen, aryl or heteroaryl; Z represents a direct bond, methylene, ethylene, vinylene, oxy, —CH2—O— or —O—CH2—; and R3—R4, p and r are as defined in the specification or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. A particular use is in cancer therapy.Type: ApplicationFiled: February 11, 2002Publication date: November 27, 2003Applicant: Zeneca Limited and Zeneca Pharma S.A.Inventors: Francis Thomas Boyle, Gareth Morse Davies, James Michael Wardleworth, Jean-Claude Arnould
-
Publication number: 20030216356Abstract: The invention provides a compound of Formula (I) wherein: R1 and R2 are independently selected from hydrogen, halogen, —CN, a hydrocarbyl group or a group of Formula (II); wherein W is aryl or a heterocyclic group, R4 is independently select from hydrogen, halogen, —OH, amino, alkanoylamino, —OPO3H2, or a hydrocarbyl group, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified or two R4 groups together form an optionally substituted cyclic or heterocyclic group; X is selected from $M(y) S+—, +—O—+, —+S(O)+—, —+S(O2)+— and —+NH—; p is an integer from 0 to 4; and q is an integer from 1 to 4; R3 and R10 are independently selected from hydrogen, lower alkyl or a group of Formula (IV): wherein Y is selected from +NH+—, —$M(Y)O$M(Y)— or a bond; Z is selected from +NH+—, —+O&ngr;&mdashType: ApplicationFiled: November 13, 2002Publication date: November 20, 2003Inventors: Jean-Claude Arnould, Thomas Geoffrey Bird, Francis Thomas Boyle, David Charles Blakey
-
Publication number: 20030096842Abstract: This invention relates to compounds of formula (I) that inhibit farnesylation of gene products through inhibition of the enzyme farnesyl-protein transferase (FPTase). The invention also relates to methods of manufacturing the compounds, pharmaceutical compositions and methods of treating diseases, especially cancer, which are mediated through farnesylation.Type: ApplicationFiled: June 20, 2002Publication date: May 22, 2003Inventors: James Michael Wardleworth, Francis Thomas Boyle, Zbigniew Matusiak
-
Publication number: 20030083348Abstract: 1 This invention relates to compounds of formula (1) that inhibit farnesylation of gene products through inhibition of the enzyme farnesyl-protein transferase (FPTase). The invention also relates to methods of manufacturing the compounds, pharmaceutical compositions and methods of treating diseases, especially cancer, which are mediated through farnesylation.Type: ApplicationFiled: April 17, 2002Publication date: May 1, 2003Inventors: James Michael Wardleworth, Francis Thomas Boyle, Zbigniew Matusiak
-
Patent number: 6541491Abstract: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S-dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.Type: GrantFiled: November 30, 2000Date of Patent: April 1, 2003Assignee: Zeneca LimitedInventors: David Huw Davies, Francis Thomas Boyle, James Michael Wardleworth, Peter Wedderburn Kenny, Peter Beverley Scholes, Zbigniew Stanely Matusiak
-
Patent number: 6414145Abstract: The present invention relates to inhibitors of ras farnesylation of Formula (I), wherein T is of Formula (1) or (2) or (3); A is aryl or heteroaryl; B is aryl or heteroaryl; X and Y represent hydrogen, or both X and Y can represent a single bond (so as to form a double bond); R1 represents a group of Formula (II) or (III), the group of Formula (II) or Formula (III) (having L or D configuration at the chiral alpha carbon in the corresponding free amino acid); R2 represents hydrogen, aryl or heteroaryl; Z represents a direct bond, methylene, ethylene, vinylene, oxy, —CH2—O— or —O—CH2—; and R3—R4, p and r are as defined in the specification or a pharmaceutically-acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.Type: GrantFiled: July 28, 1999Date of Patent: July 2, 2002Assignees: Zeneca Limited, Zeneca Pharma S.A.Inventors: Francis Thomas Boyle, Gareth Morse Davies, James Michael Wardleworth, Jean-Claude Arnould